Pharma Industry News

Astria Therapeutics’ edge in an ultra-rare disease

3 years ago
by David Miller
952 Views

With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]